Today's Research: ACADIA Pharma, Sarepta Therapeutics, Medivation, and Cell Therapeutics

LONDON, July 17, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

On Tuesday, July 16, 2013, shares in biotechnology companies ended mostly lower, tracking losses in the broader market. The major movers in the industry included ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Medivation Inc. (NASDAQ: MDVN), and Cell Therapeutics Inc. (NASDAQ: CTIC).  AAAResearchReports.com has completed their technical analysis on ACAD, SRPT, MDVN, and CTIC and these free reports are accessible by registering at:

http://www.aaaresearchreports.com/register/  

Shares in ACADIA Pharmaceuticals Inc. fell sharply on Tuesday, reversing some of their recent gains. The company's shares initially rose to a 52-week high of $20.49, but gave up all their gains to end the session 1.78% lower at $19.92. A total of 2.82 million shares were traded which is below the daily average volume of 3.94 million. Despite Tuesday's pullback, the company's shares have gained 7.33% in the last three trading sessions. Sign up for free technical research on ACAD at:

http://www.AAAResearchReports.com/ACAD071713.pdf

Sarepta Therapeutics Inc.'s stock moved lower on Tuesday, as the broader market fell. The company's shares initially hit a 52-week high of $45.46. However, the stock pared its initial gains and closed the session 1.52% lower at $43.93. A total of 1.16 million shares were traded which is below the daily average volume of 1.41 million. The company's shares have gained 0.78% in the last three trading sessions and 29.24% in the last three months, thus outperforming the S&P 500. Be sure to read our latest technical research on SRPT by registering at:

http://www.AAAResearchReports.com/SRPT071713.pdf

Shares in Medivation Inc. fell sharply on Tuesday, reversing most of its recent gains. The company's shares oscillated between $55.35 and $58.15 before finishing the day 3.04% lower at $55.50. A total of 898,598 shares were traded which is below the daily average volume of 1.13 million. The company's shares have gained 0.56% in the last three trading sessions, and 9.12% in the past one month. With the recent gains, the stock has edged up closer to its 52-week high of $59.24. Sign up and read the complimentary report on MDVN at:

http://www.AAAResearchReports.com/MDVN071713.pdf

Cell Therapeutics Inc.'s stock moved lower on Tuesday, closing at $1.06, down 0.93% from its previous closing price. The company's shares fluctuated between $1.05 and $1.08. A total of 537,628 shares were traded which is below the daily average volume of 1.51 million. The company's shares are currently trading below their 50-day and 200-day moving averages. The free report on CTIC can be downloaded by signing up now at:

http://www.AAAResearchReports.com/CTIC071713.pdf

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE AAA Research Reports

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED